Adoptive cell transfer

Autolus Therapeutics to Present New Data at the ASH Annual Meeting

Retrieved on: 
Venerdì, Novembre 2, 2018
Medicine, Clinical medicine, Cancer, Tumors of the hematopoietic and lymphoid tissues, CD19, Lymphoma, Cancer treatments, Immunology, Leukemia, Adoptive cell transfer, Kite Pharma

By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies.

Key Points: 
  • By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies.
  • The trial is also enrolling patients who previously received CD19 or CD22 targeting therapies including other CAR T cell therapy.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
  • Autolus Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Global Genetic Modification Therapies Clinical Market Report 2018-2023: Focus on Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

Retrieved on: 
Giovedì, Settembre 27, 2018
Biology, Biotechnology, Molecular biology, Emerging technologies, Applied genetics, Biological engineering, Gene therapy, Genetic engineering, Genetically modified organism, Chimeric antigen receptor, Induced stem cells, Adoptive cell transfer

The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" report has been added to ResearchAndMarkets.com's offering.
  • The study scope includes clinical therapies using gene editing, gene therapy, genetically modified cell therapy (chimeric antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms.
  • Genetic modification therapies are advanced therapies that use genetic material (i.e., DNA or RNA) to treat diseases.
  • The four main genetic modification therapy platform technologies covered in this report include gene therapies, genetically modified cell therapies, RNA therapies, and gene editing.

GigaMune Wins Grant from National Cancer Institute to Develop Cell Therapy Based on Tumor Infiltrating Lymphocytes

Retrieved on: 
Martedì, Settembre 11, 2018
Lymphatic system, Medicine, Immunology, Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Immune system, T cells, TILS, T-cell receptor, Adoptive cell transfer

SAN FRANCISCO, Sept. 11, 2018 /PRNewswire-PRWeb/ -- On September 1, 2018, GigaMune secured a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

Key Points: 
  • SAN FRANCISCO, Sept. 11, 2018 /PRNewswire-PRWeb/ -- On September 1, 2018, GigaMune secured a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).
  • The project is focused on developing novel engineered cell therapies derived from tumor infiltrating lymphocytes (TILs).
  • The "recombinant TIL" therapy retains the polyclonal TCRs of that patient's TILs but does not require the extended cell culture methods used in conventional TIL therapy.
  • GigaMune Inc. is a cancer cell therapy company focused on T cell receptor (TCR) discovery and development, founded in 2017 as a spin-out from GigaGen.

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

Retrieved on: 
Giovedì, Settembre 6, 2018
Medicine, Clinical medicine, Immunology, Immune system, T cells, Cancer treatments, Adoptive cell transfer, Immunotherapy, Cancer immunotherapy, Chimeric antigen receptor, Agenus, ImmTAC

Dr. Plewa will present two posters on the T-Rx Platform technology, a proprietary state-of-the-art drug discovery engine that enables rapid discovery of T cell receptors (TCRs).

Key Points: 
  • Dr. Plewa will present two posters on the T-Rx Platform technology, a proprietary state-of-the-art drug discovery engine that enables rapid discovery of T cell receptors (TCRs).
  • AgenTus employs naturally-derived and engineered receptors, specifically T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer.
  • AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

Regenerative Medicine Market, 2022

Retrieved on: 
Martedì, Giugno 12, 2018
Medicine, Biology, Clinical medicine, Cancer treatments, Virotherapy, Biotechnology, Immunotherapy, Gene therapy, Adoptive cell transfer, Chimeric antigen receptor

3.8 What is the Future of Stem Cell Trials?

Key Points: 
  • 3.8 What is the Future of Stem Cell Trials?
  • 7.1 What do Investors Want from Cell & Gene Therapy Companies?
  • 7.6 What Cell & Gene Companies are the Most Promising in 2018?
  • 13.2 Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA

Global T-Cell Immunotherapy Market to 2030: With Steady Growth in the Development Pipeline, T-Cell based Therapies have Emerged as a Promising Segment of the Immunotherapy Market

Retrieved on: 
Venerdì, Giugno 8, 2018
Medicine, Clinical medicine, Cancer, Cancer treatments, Immune system, Virotherapy, Immunotherapy, Chimeric antigen receptor, Immune checkpoint, Cancer immunotherapy, Adoptive cell transfer

The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies).

Key Points: 
  • The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies).
  • Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone.
  • Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects.
  • It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies.

OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

Retrieved on: 
Lunedì, Giugno 4, 2018
Medicine, Clinical medicine, Melanoma, Cancer, RTT, Immunology, Programmed cell death protein 1, Antineoplastic drugs, Ipilimumab, Adoptive cell transfer

The Company anticipates that enrollment in stage 1 will be completed by the third quarter 2018.

Key Points: 
  • The Company anticipates that enrollment in stage 1 will be completed by the third quarter 2018.
  • OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer.
  • The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies.
  • In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform.